Thromboprophylaxis in multiple myeloma

Abstract

Venous thromboembolism (VTE) in multiple myeloma (MM) can be secondary to patient-, disease-, and/or treatment-related factors. The development of VTE may result in significant morbidity with the highest risk during the first year after diagnosis. This clinical review provides an evidence-based summary to guide practicing oncologists in the use of anticoagulation to prevent VTE in multiple myeloma and includes anticoagulation efficacy and adverse effect profile. We highlight the pathophysiology of VTE in MM, the use of various risk prediction tools, and the current recommendations for the use of different anticoagulants in prophylaxis of VTE.

Keywords:

• Multiple myeloma
• venous thromboembolism
• pulmonary embolism
• deep venous thrombosis
• anticoagulation
• DOACs

Disclosure statement

The authors report there are not competing interests to declare.